Mr. Hugh MacNaught reports

VENTRIPOINT AND ASCEND CARDIOVASCULAR SIGN TERM SHEET FOR INTEGRATION OF VMS+ INTO ASCEND'S GEN3ECHO(TM) PLATFORM

Ventripoint Diagnostics Ltd. and Ascend Cardiovascular, a leading provider of cardiovascular IT (information technology) solutions, have signed a term sheet defining the general terms and conditions for a non-exclusive licence to Ventripoint's VMS+ proprietary technology. The two parties expect to execute the licence agreement within 30 days.

Ascend Cardiovascular has over two decades of experience in cardiovascular IT and is leader in cardiology workflow solutions. Ascend's clinical reporting, device interfaces and analytics are used daily by some of the top institutions and hospital systems in North America. Ascend has introduced Gen3Echo, a first of a kind, comprehensive platform that combines artificial intelligence and machine learning technology to accelerate, simplify and automate echo workflow.

"Ascend is on a mission to provide a powerful, fully integrated, best-of-breed echocardiography workflow solution to its customers," stated Dr. Jeff Soble, chief executive officer of Ascend Cardiovascular. "Integration of Gen3Echo with Ventripoint's innovative solution for 3-D visualization, and in particular their unique ability to synthesize 3-D images from 2-D echo data, will provide tremendous value to paediatric and adult echocardiographers in the care of their most complex patients."

Ascend intends to fully integration Ventripoint's VMS+ technology with Ascend's Gen3Echo platform. This agreement is the next natural step for Ascend and Ventripoint as they both move to enhance cardiovascular diagnostics and improve patient care. The objective of this agreement is to fully align VMS+ with Gen3Echo workflow to improve diagnostic accuracy, streamline workflows and enhance patient experience in cardiovascular imaging.

"Under the existing letter of intent, we demonstrated the attractiveness of the combined Gen3Echo and VMS+ offering," said Hugh MacNaught, president and chief executive officer of Ventripoint. "This licensing agreement takes us to a deeper level of integration, offering customers a seamless experience leveraging both best-in-class solutions. Our teams continue to work closely together to fully integrate our VMS+ technology into Ascend's Gen3Echo platform. We will work with Ascend on commercialization of this new initiative, beginning with a combined outreach to paediatric centres."

Ventripoint and Ascend have highly complementary technologies and capabilities within the field of cardiovascular imaging. Ascend possesses clinical and industry knowledge, proprietary structured reporting, and its zero-footprint DICOM viewer honed for echo automation and advance analysis. Ventripoint provides proprietary AI-based diagnostic technologies, research capabilities and technical expertise in cardiovascular imaging and analysis. The combination of the unique expertise and resources of both companies enable novel solutions that address existing challenges within clinical practice.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.